We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
+51.15%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$164M
AUM Growth
-$161M
Cap. Flow
-$193M
Cap. Flow %
-117.42%
Top 10 Hldgs %
81.58%
Holding
31
New
8
Increased
4
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
EYPT icon
EyePoint Inc
EYPT
+$4.49M
2
SWTX
SpringWorks Therapeutics
SWTX
+$4.1M
3
BHVN icon
Biohaven
BHVN
+$3.39M
4
TDOC icon
Teladoc Health
TDOC
+$2.08M
5
ARDX icon
Ardelyx
ARDX
+$516K

Sector Composition

Rank Sector Weight
1 Healthcare 55.58%
2 Energy 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BHVN icon
1
Biohaven
BHVN
$2.07B
$30.7M 18.65%
716,427
+108,900
+18% +$3.39M
PACB icon
2
CALL
Pacific Biosciences
PACB
$432M
$17.5M 10.66%
1,787,100
-7,305,900
-80% -$59.7M
TDOC icon
3
CALL
Teladoc Health
TDOC
$1.69B
$13.8M 8.38%
+639,600
New +$11.8M
PACB icon
4
Pacific Biosciences
PACB
$432M
$13.5M 8.21%
1,376,795
-261,600
-16% -$2.14M
QDEL icon
5
QuidelOrtho
QDEL
$1.14B
$13M 7.91%
176,544
-14,700
-8% -$994K
QDEL icon
6
CALL
QuidelOrtho
QDEL
$1.14B
$12.7M 7.71%
172,100
-1,697,900
-91% -$115M
EYPT icon
7
EyePoint Inc
EYPT
$1B
$9.28M 5.64%
+401,557
New +$4.49M
SWTX
8
CALL
DELISTED
SpringWorks Therapeutics
SWTX
$9.13M 5.55%
+250,000
New +$6.52M
ARDX icon
9
CALL
Ardelyx
ARDX
$1.25B
$8.84M 5.37%
+1,425,000
New +$6.39M
SWTX
10
DELISTED
SpringWorks Therapeutics
SWTX
$5.73M 3.49%
+157,083
New +$4.1M
ARDX icon
11
Ardelyx
ARDX
$1.25B
$5.36M 3.26%
864,700
+115,000
+15% +$516K
EYPT icon
12
CALL
EyePoint Inc
EYPT
$1B
$5.09M 3.1%
+220,300
New +$2.46M
FORA
13
DELISTED
Forian
FORA
$4M 2.43%
1,368,067
BHVN icon
14
CALL
Biohaven
BHVN
$2.07B
$3.21M 1.95%
75,000
-1,498,000
-95% -$46.6M
BCRX icon
15
BioCryst Pharmaceuticals
BCRX
$2.48B
$3.21M 1.95%
535,558
-19,964
-4% -$116K
WBA
16
CALL
DELISTED
Walgreens Boots Alliance
WBA
$2.61M 1.59%
+100,000
New +$2.24M
TDOC icon
17
Teladoc Health
TDOC
$1.69B
$2.43M 1.48%
+112,861
New +$2.08M
IMMP
18
Immutep
IMMP
$57M
$1.24M 0.75%
516,430
AGEN
19
Agenus
AGEN
$275M
$1.17M 0.71%
70,848
-35,000
-33% -$580K
BIIB icon
20
Biogen
BIIB
$30.4B
$624K 0.38%
2,412
WGS icon
21
GeneDx Holdings
WGS
$1.84B
$490K 0.3%
178,354
-816,226
-82% -$1.9M
AXDX
22
DELISTED
Accelerate Diagnostics
AXDX
$437K 0.27%
111,575
-24,953
-18% -$132K
VTNR
23
DELISTED
Vertex Energy, Inc
VTNR
$170K 0.1%
50,000
+24,700
+98% +$96.9K
BDSX icon
24
Biodesix
BDSX
$218M
$112K 0.07%
3,047
+943
+45% +$29.6K
DMTK
25
DELISTED
DermTech, Inc. Common Stock
DMTK
$83.5K 0.05%
47,687

Similar funds

Oracle Investment Management's Q4 2023 Portfolio in Review

As of Q4 2023, Oracle Investment Management held 31 positions worth $164M, down 50% from $326M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Oracle Investment Management withdrew a net $193M in Q4 2023, closing 5 positions and reducing 9 holdings. Its most notable exit was MannKind Corp, an estimated $1.24M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 20% a quarter earlier, followed by Energy.

Against the trend, Oracle Investment Management opened a new position in EyePoint Inc worth $9.28M.

  • Oracle Investment Management's largest Q4 2023 buy was EyePoint Inc: 401,557 shares worth $9.28M.
  • Oracle Investment Management added most to Biohaven in Q4 2023, an estimated $3.39M increase.
  • Oracle Investment Management's biggest Q4 2023 reduction was Pacific Biosciences, cutting an estimated $2.14M.
  • Oracle Investment Management fully exited MannKind Corp in Q4 2023, selling an estimated $1.24M.
  • Oracle Investment Management's ten largest holdings make up 82% of its $164M portfolio in Q4 2023.
  • Oracle Investment Management opened 8 new positions and closed 5 in Q4 2023.
  • Oracle Investment Management's portfolio value fell 50% quarter-over-quarter to $164M.

Based on Oracle Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.